Press Releases
Search by Year
-
27 Mar 2024
SITES - Press Release
Dual 510(k) clearance and CLIA-waiver approval for the BIOFIRE® SPOTFIRE® R/ST Panel
bioMérieux, a world leader in the field of in vitro diagnostics, has received U.S. Food and Drug Administration (FDA) 510(k) clearance and Clinical Laboratory Improvement Amendments (CLIA) waiver approval for the BIOFIRE® SPOTFIRE® Respiratory/Sore Throat (R/ST) Panel.
-
14 Mar 2024
SITES - Press Release
bioMérieux – 2023 Financial Results
Today bioMérieux released its 2023 financial results. Consolidated sales amounted to €3,675 million in 2023, up 6.6% like-for-like from €3,589 million in the prior year period.
-
16 Jan 2024
Appointments
bioMérieux announces nomination of two new Executive Committee members to lead Medical Affairs and R&D
bioMérieux, a world leader in the field of in vitro diagnostics, announces the appointment of two new Executive Committee members: Dr. Charles K. Cooper as Executive Vice President, Chief Medical Officer, effective January 2nd, 2024; Céline Roger-Dalbert as Executive Vice President Research and Development, effective March 1st, 2024.
-
08 Jan 2024
Mergers & Acquisitions
bioMérieux acquires LUMED to reinforce its software portfolio in the fight against antimicrobial resistance
bioMérieux, a world leader in the field of in vitro diagnostics, announces the acquisition of LUMED, a software company that has developed a clinical decision support system to help hospitals optimize antimicrobial prescriptions and monitor healthcare-associated infections.
-
26 Oct 2023
Financial Information
Third-Quarter 2023 Business Review
bioMérieux, a world leader in the field of in vitro diagnostics, today releases its business review for the nine months ended September 30, 2023. Consolidated sales amounted to €2,668 million for the first nine months of 2023.
-
19 Oct 2023
Financial Information
bioMérieux makes strategic investment in Oxford Nanopore
Oxford Nanopore Technologies plc (LSE: ONT) (“Oxford Nanopore”), the company delivering a new generation of nanopore-based molecular sensing technology, and bioMérieux SA, a world leader in the field of in vitro diagnostics (“IVD”) today announce that bioMérieux is making an immediate £70M investment in Oxford Nanopore.
-
13 Oct 2023
Business & Solutions
bioMérieux announces CE-marking of VIDAS® TBI (GFAP, UCH-L1)
bioMérieux, a world leader in the field of in vitro diagnostics, announces the CE-marking of VIDAS® TBI (GFAP, UCH-L1), a blood test to support assessment of patients with mild traumatic brain injury (mTBI), based on a unique combination of brain biomarkers: GFAP and UCH-L1*.
-
11 Oct 2023
Partnerships
Launch of a new industrial chair, in Lyon on viral respiratory infections
On October 11, 2023, the REVIDA Industrial Chair for Respiratory Infectious Diseases, led by researcher Sophie Trouillet-Assant (UCBL / HCL), was officially launched by Claude Bernard Lyon 1 University, Hospices Civils de Lyon, and bioMérieux, with the support of the Agence nationale de la recherche (National research agency, in France).
-
22 Sep 2023
Business & Solutions
bioMérieux submits Dual 510(k) and CLIA-waiver application to FDA for the BIOFIRE® SPOTFIRE® Respiratory/Sore Throat (R/ST) Panel
bioMérieux, a world leader in the field of in vitro diagnostics, has submitted the BIOFIRE® SPOTFIRE® Respiratory/Sore Throat (R/ST) Panel to U.S. Food and Drug Administration (FDA) for a dual 510(k) clearance and CLIA1-waiver. This panel is already CE-marked (IVDD).
-
01 Sep 2023
Financial Information
First-Half 2023 Results
Consolidated sales amounted to €1,770 million in first-half 2023, a robust growth like-for-like of 8.3% from €1,658 million in the prior year.